The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstructive sleep apnea ... promotes weight loss, with patients ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

The medication also promotes weight loss, with patients losing an average ... There will likely be insurance coverage for Zepbound as a sleep apnea treatment; however, as a newly approved ...

Sleep expert Dr. Abhay Sharma talks about how Zepbound is now approved by the FDA for the treatment of moderate to severe ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

“For some patients who have sleep apnea, combining another treatment with Zepbound may be ideal,” the association says. “Furthermore, weight loss from Zepbound must be maintained over time ...

SURMOUNT-OSA trials: Zepbound ... for weight loss. In December, the FDA approved Zepbound as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea ...

“For some patients who have sleep apnea, combining another treatment with Zepbound may be ideal,” the association says. “Furthermore, weight loss from Zepbound must be maintained over time ...

Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss drugs like Zepbound and Novo Nordisk's Ozempic ...